Meeting
2022 ASCO Annual Meeting
Design and initiation of an adaptive, randomized, controlled study of berubicin, a topoisomerase 2 poison that crosses the blood brain barrier (BBB), for the treatment of recurrent glioblastoma multiforme (GBM) after first-line therapy.
Authors
Sandra Silberman
Cortice Biosciences, New York, NY
Sandra Silberman , Sigmund H. Hsu , Zena Muzyczenko , Donald Picker , Waldemar Priebe
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT04762069
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2083)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2083
Abstract #
TPS2083
Poster Bd #
416a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.
First Author: Yoshiki Arakawa
Poster
2016 ASCO Annual Meeting
Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, as monotherapy in epidermal growth factor receptor (EGFR) amplified, recurrent glioblastoma (GBM).
First Author: Martin J. Van Den Bent
Poster
2021 ASCO Annual Meeting
Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.
First Author: Yazmin Odia
Poster
2020 ASCO Virtual Scientific Program
Association of peripheral blood CD4+ T-cell depletion under temozolomide with inferior survival of patients with IDH wildtype glioblastoma.
First Author: Michael Weller